George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Apr 2020 16:37

RNS Number : 6322J
Circassia Pharmaceuticals Plc
14 April 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

CIRCASSIA PHARMACEUTICALS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Harwood Capital LLP (as investment adviser/manager) and 1. Oryx International Growth Fund Limited 2. Harwood Capital LLP and 3. North Atlantic Smaller Companies Investment Trust plc

City and country of registered office (if applicable)

1. Guernsey

2. & 3. London, United Kingdom

 

4. Full name of shareholder(s) (if different from 3.)v

Name

1. Oryx International Growth Fund Limited

2. Harwood Capital LLP

3. North Atlantic Smaller Companies Investment Trust plc

 

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

9th April 2020

6. Date on which issuer notified (DD/MM/YYYY):

14th April 2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

1. 40,000,000

2. 70,000

3, 1,200,000

 

 

 

1. 10.66%

2. 0.02%

3. 0.32%

 

375,210,543

Position of previous notification (if

applicable)

1. 35,000,000

2. 70,000

 

 

 

 9.33%

 0.02%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJVD3B281.

1.

2.

3.

 

40,000,000

70,000

1,200,000

 

 

10.66%

0.02%

0.32%

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

41,270,000

11.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

10.66

0

10.66

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

Oryx International Growth Fund Ltd

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

0.02

0

0.02

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

 0.32

 

0.32

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

North Atlantic Smaller Companies Investment Trust plc

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

Oxford, UK

Date of completion

14th April 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUSOVRRVUSAAR
Date   Source Headline
27th Jan 202011:47 amRNSHolding(s) in Company
21st Jan 20201:46 pmRNSHolding(s) in Company
17th Jan 20203:34 pmRNSHolding(s) in Company
15th Jan 20202:22 pmRNSHolding(s) in Company
13th Jan 20203:13 pmRNSHolding(s) in Company
10th Jan 20205:39 pmRNSHolding(s) in Company
10th Jan 20205:38 pmRNSHolding(s) in Company
10th Jan 20203:18 pmRNSInvestment in Circassia Pharmaceuticals plc
9th Jan 20204:26 pmRNSHolding(s) in Company
9th Jan 20207:00 amRNSCircassia Announces Business Update
3rd Jan 202011:53 amRNSHolding(s) in Company
31st Dec 20197:00 amRNSTotal Voting Rights
19th Dec 20192:03 pmRNSGrant of Options
19th Dec 20197:04 amRNSUpdate on Licensing Agreement with BeyondAir Inc.
17th Dec 201910:50 amRNSHolding(s) in Company
13th Dec 20194:05 pmRNSHolding(s) in Company
6th Dec 201912:25 pmRNSDirector/PDMR Shareholding
5th Dec 20197:00 amRNSCircassia Announces Board Changes
3rd Dec 20194:33 pmRNSHolding(s) in Company
29th Nov 20197:00 amRNSTotal Voting Rights Update
27th Nov 20191:38 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSHolding(s) in Company
26th Nov 20194:55 pmRNSHolding(s) in Company
26th Nov 20194:51 pmRNSHolding(s) in Company
25th Nov 20195:38 pmRNSHolding(s) in Company
25th Nov 20195:35 pmRNSHolding(s) in Company
4th Nov 20192:48 pmRNSHolding(s) in Company
31st Oct 20197:00 amRNSTotal Voting Rights Update
21st Oct 20197:00 amRNSUS launch of Duaklir at CHEST 2019
17th Oct 20195:34 pmRNSGrant of options
4th Oct 20194:30 pmRNSHolding(s) in Company
1st Oct 201911:25 amRNSDirector/PDMR Shareholding
30th Sep 201911:06 amRNSTotal Voting Rights
30th Sep 201911:02 amRNSBlock listing Interim Review
26th Sep 20197:00 amRNSInterim Results for Six Months Ended 30 June 2019
20th Sep 20193:37 pmRNSHolding(s) in Company
19th Sep 20195:40 pmRNSHolding(s) in Company
18th Sep 20195:26 pmRNSHolding(s) in Company
18th Sep 20195:21 pmRNSHolding(s) in Company
17th Sep 20191:10 pmRNSHolding(s) in Company
17th Sep 201912:01 pmRNSHolding(s) in Company
16th Sep 20194:51 pmRNSHolding(s) in Company
13th Sep 20195:57 pmRNSBlock listing Interim Review
12th Sep 20197:00 amRNSNotice of Results and Appointment of Joint Broker
30th Aug 20197:00 amRNSTotal Voting Rights
23rd Aug 20195:23 pmRNSDirector/PDMR Shareholding
12th Aug 20197:00 amRNSAppointment of Jonathan Emms as COO
31st Jul 20191:55 pmRNSTotal Voting Rights
22nd Jul 20194:12 pmRNSHolding(s) in Company
9th Jul 20191:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.